View Item 

Show simple item record

Long‐term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

dc.contributor.authorLucey, Michael R.en_US
dc.contributor.authorTerrault, Norahen_US
dc.contributor.authorOjo, Loluen_US
dc.contributor.authorHay, J. Eileenen_US
dc.contributor.authorNeuberger, Jamesen_US
dc.contributor.authorBlumberg, Emilyen_US
dc.contributor.authorTeperman, Lewis W.en_US
dc.date.accessioned2013-01-03T19:47:04Z
dc.date.available2014-03-03T15:09:24Zen_US
dc.date.issued2013-01en_US
dc.identifier.citationLucey, Michael R.; Terrault, Norah; Ojo, Lolu; Hay, J. Eileen; Neuberger, James; Blumberg, Emily; Teperman, Lewis W. (2013). "Long‐term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation ." Liver Transplantation 19(1): 3-26. <http://hdl.handle.net/2027.42/95693>en_US
dc.identifier.issn1527-6465en_US
dc.identifier.issn1527-6473en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/95693
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titleLong‐term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherLiver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdomen_US
dc.contributor.affiliationotherDepartment of Surgery, NYU Transplant Associates, New York, NYen_US
dc.contributor.affiliationotherDivision of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PAen_US
dc.contributor.affiliationotherDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WIen_US
dc.contributor.affiliationotherGastroenterology Division, Department of Medicine, University of California San Francisco, San Francisco, CAen_US
dc.contributor.affiliationotherMayo Clinic, Rochester, MNen_US
dc.contributor.affiliationotherDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, 4245 MFMB, Madison, WI 53792‐5124en_US
dc.identifier.pmid23281277en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/95693/1/23566_ftp.pdf
dc.identifier.doi10.1002/lt.23566en_US
dc.identifier.sourceLiver Transplantationen_US
dc.identifier.citedreferenceFrassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV‐1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816 ‐ 2820.en_US
dc.identifier.citedreferenceLoomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and lamivudine improve hepatitis B‐related outcomes after liver transplantation: meta‐analysis. Clin Gastroenterol Hepatol 2008; 6: 696 ‐ 700.en_US
dc.identifier.citedreferenceRao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta‐analysis. Transpl Int 2009; 22: 387 ‐ 394.en_US
dc.identifier.citedreferenceKatz LH, Paul M, Guy DG, Tur‐Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta‐analysis. Transpl Infect Dis 2010; 12: 292 ‐ 308.en_US
dc.identifier.citedreferenceDan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost‐effectiveness analysis. Liver Transpl 2006; 12: 736 ‐ 746.en_US
dc.identifier.citedreferenceFox AN, Terrault NA. The option of HBIG‐free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189 ‐ 1197.en_US
dc.identifier.citedreferenceLucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390 ‐ 1396.en_US
dc.identifier.citedreferenceTerrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192 ‐ 1204.en_US
dc.identifier.citedreferenceKalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, et al. Clinical outcome of HCV‐related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009; 22: 172 ‐ 181.en_US
dc.identifier.citedreferenceForman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889 ‐ 896.en_US
dc.identifier.citedreferenceNeumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long‐term outcome of liver transplants for chronic hepatitis C: a 10‐year follow‐up. Transplantation 2004; 77: 226 ‐ 231.en_US
dc.identifier.citedreferenceLake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549 ‐ 557.en_US
dc.identifier.citedreferenceWiesner RH, Sorrell M, Villamil F; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1 ‐ S9.en_US
dc.identifier.citedreferenceVeldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426 ‐ 2433.en_US
dc.identifier.citedreferenceXirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated‐interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta‐analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699 ‐ 709.en_US
dc.identifier.citedreferenceFiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861 ‐ 871.en_US
dc.identifier.citedreferenceNeuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 2003; 9: 539 ‐ 546.en_US
dc.identifier.citedreferenceHubscher SG, Elias E, Buckels JA, Mayer AD, McMaster P, Neuberger JM. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993; 18: 173 ‐ 184.en_US
dc.identifier.citedreferenceNeuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10: 488 ‐ 491.en_US
dc.identifier.citedreferenceJoshi D, Bjarnason I, Belgaumkar A, O'Grady J, Suddle A, Heneghan MA, et al. The impact of inflammatory bowel disease post‐liver transplantation for primary sclerosing cholangitis. Liver Int; doi:10.111/j1478‐ 3231.2011.02677.en_US
dc.identifier.citedreferenceFosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1 ‐ 15.en_US
dc.identifier.citedreferenceTripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009; 29: 286 ‐ 296.en_US
dc.identifier.citedreferenceLucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17: 751 ‐ 759.en_US
dc.identifier.citedreferenceDiMartini A, Dew MA, Chaiffetz D, Fitzgerald MG, Devera ME, Fontes P. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long‐term survival. Am J Transplant 2011; 11: 1287 ‐ 1295.en_US
dc.identifier.citedreferenceAngulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006; 12: 523 ‐ 534.en_US
dc.identifier.citedreferenceDumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Non‐alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 2010; 105: 613 ‐ 620.en_US
dc.identifier.citedreferenceCharlton M, Kasparova P, Weston S, Lindor K, Maor‐Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608 ‐ 614.en_US
dc.identifier.citedreferenceDureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91: 684 ‐ 689.en_US
dc.identifier.citedreferenceEddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia, PA: American College of Physicians; 1996.en_US
dc.identifier.citedreferenceCommittee to Advise the Public Health Service on Clinical Practice Guidelines, Institute of Medicine; Field MJ, Lohr KN, eds. Clinical Practice Guidelines: Directions of a New Program. Washington, DC: National Academies Press; 1990.en_US
dc.identifier.citedreferenceAmerican Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925 ‐ 926.en_US
dc.identifier.citedreferenceGuyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, Schünemann HJ; for GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924 ‐ 926.en_US
dc.identifier.citedreferenceDevlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926 ‐ 933.en_US
dc.identifier.citedreferenceOjo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931 ‐ 940.en_US
dc.identifier.citedreferenceTome S, Wells JT, Said A, Lucey MR. Quality of life after liver transplantation. A systematic review. J Hepatol 2008; 48: 567 ‐ 577.en_US
dc.identifier.citedreferenceShah JN, Haigh WG, Lee SP, Lucey MR, Brensinger CM, Kochman ML, et al. Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol 2003; 98: 1861 ‐ 1867.en_US
dc.identifier.citedreferenceSafdar N, Said A, Lucey MR, Knechtle SJ, D'Alessandro A, Musat A, et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis 2004; 39: 517 ‐ 525.en_US
dc.identifier.citedreferenceBanff Working Group, Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489 ‐ 501.en_US
dc.identifier.citedreferenceMusat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor‐specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500 ‐ 510.en_US
dc.identifier.citedreferenceGuichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long‐term follow‐up and predictive factors. Liver Transpl 2006; 12: 1390 ‐ 1402.en_US
dc.identifier.citedreferenceGuichelaar MM, Schmoll J, Malinchoc M, Hay JE. Fractures and avascular necrosis before and after orthotopic liver transplantation: long‐term follow‐up and predictive factors. Hepatology 2007; 46: 1198 ‐ 1207.en_US
dc.identifier.citedreferenceGonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End‐stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin‐based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934 ‐ 1939.en_US
dc.identifier.citedreferenceParamesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post‐liver transplant acute renal failure: factors predicting development of end‐stage renal disease. Clin Transplant 2004; 18: 94 ‐ 99.en_US
dc.identifier.citedreferenceGonwa TA, McBride MA, Mai ML, Wadei HM. Kidney transplantation after previous liver transplantation: analysis of the Organ Procurement Transplant Network database. Transplantation 2011; 92: 31 ‐ 35.en_US
dc.identifier.citedreferenceWatt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post‐liver transplant: results of the NIDDK long‐term follow‐up study. Am J Transplant 2010; 10: 1420 ‐ 1427.en_US
dc.identifier.citedreferenceWagner D, Kniepeiss D, Stiegler P, Zitta S, Bradatsch A, Robatscher M, et al. The assessment of GFR after orthotopic liver transplantation using cystatin C and creatinine‐based equations. Transpl Int 2012; 25: 527 ‐ 536.en_US
dc.identifier.citedreferenceStevens LA, Padala S, Levey AS. Advances in glomerular filtration rate‐estimating equations. Curr Opin Nephrol Hypertens 2010; 19: 298 ‐ 307.en_US
dc.identifier.citedreferenceKeane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004 ‐ 1010.en_US
dc.identifier.citedreferenceWatson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)‐based to sirolimus‐based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694 ‐ 1702.en_US
dc.identifier.citedreferenceYoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen vs. a standard‐dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064 ‐ 1072.en_US
dc.identifier.citedreferenceNeuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al.; for ReSpECT Study Group. Delayed introduction of reduced‐dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327 ‐ 336.en_US
dc.identifier.citedreferenceNair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126 ‐ 129.en_US
dc.identifier.citedreferenceSaner FH, Cicinnati VR, Sotiropoulos G, Beckebaum S. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver Int 2012; 32: 179 ‐ 188.en_US
dc.identifier.citedreferenceDemirci G, Becker T, Nyibata M, Lueck R, Bektas H, Lehner F, et al. Results of combined and sequential liver‐kidney transplantation. Liver Transpl 2003; 9: 1067 ‐ 1078.en_US
dc.identifier.citedreferenceFabrizi F, Dixit V, Martin P, Messa P. Chronic kidney disease after liver transplantation: recent evidence. Int J Artif Organs 2010; 33: 803 ‐ 811.en_US
dc.identifier.citedreferenceKuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new‐onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89: 1134 ‐ 1140.en_US
dc.identifier.citedreferenceChen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta‐analysis of clinical studies. Transpl Int 2009; 22: 408 ‐ 415.en_US
dc.identifier.citedreferenceLaryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109 ‐ 1114.en_US
dc.identifier.citedreferenceDelgado‐Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M, et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193 ‐ 201.en_US
dc.identifier.citedreferenceDemirci MS, Toz H, Yilmaz F, Ertilav M, Asci G, Ozkahya M, et al. Risk factors and consequences of post‐transplant diabetes mellitus. Clin Transplant 2010; 24: E170 ‐ E177.en_US
dc.identifier.citedreferenceHeisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta‐analysis. Am J Transplant 2004; 4: 583 ‐ 595.en_US
dc.identifier.citedreferenceChobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; for National Heart, Lung, and Blood Institute Joint National Committee on Prevention, DetectionEvaluation and Treatment of High Blood Pressure and National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560 ‐ 2572.en_US
dc.identifier.citedreferenceTextor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6: 521 ‐ 530.en_US
dc.identifier.citedreferenceGalioto A, Semplicini A, Zanus G, Fasolato S, Sticca A, Boccagni P, et al. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. Liver Transpl 2008; 14: 1020 ‐ 1028.en_US
dc.identifier.citedreferenceWatt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199 ‐ 206.en_US
dc.identifier.citedreferenceLaish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15 ‐ 22.en_US
dc.identifier.citedreferenceRichards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461 ‐ 466.en_US
dc.identifier.citedreferenceEverhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998; 4: 285 ‐ 296.en_US
dc.identifier.citedreferenceEngels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891 ‐ 1901.en_US
dc.identifier.citedreferenceWatt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long‐term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010 ‐ 2017.en_US
dc.identifier.citedreferenceFinkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009; 9: 2355 ‐ 2361.en_US
dc.identifier.citedreferenceHerrero JI, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl 2011; 17: 402 ‐ 408.en_US
dc.identifier.citedreferenceNishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer 2008; 7: 260 ‐ 266.en_US
dc.identifier.citedreferenceSimon S. New screening guidelines for cervical cancer. http://www.cancer.org/Cancer/news/new‐screening‐guidelines‐for‐cervical‐cancer. Published March 14, 2012. Accessed October 2012.en_US
dc.identifier.citedreferenceRoberts JP. Tumor surveillance—what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005; 11 ( suppl 2 ): S45 ‐ S46.en_US
dc.identifier.citedreferenceLiang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, et al. Sirolimus‐based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta‐analysis. Liver Transpl 2012; 18: 62 ‐ 69.en_US
dc.identifier.citedreferenceMass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation 1996; 62: 476 ‐ 479.en_US
dc.identifier.citedreferenceCundy TF, O'Grady JG, Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut 1990; 31: 337 ‐ 338.en_US
dc.identifier.citedreferenceArmenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Gulati R, McGrory CH, Coscia LA. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2005: 69 ‐ 83.en_US
dc.identifier.citedreferenceBurra P, Germani G, Masier A, De Martin E, Gambato M, Salonia A, et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation 2010; 89: 1425 ‐ 1429.en_US
dc.identifier.citedreferenceHo JK, Ko HH, Schaeffer DF, Erb SR, Wong C, Buczkowski AK, et al. Sexual health after orthotopic liver transplantation. Liver Transpl 2006; 12: 1478 ‐ 1484.en_US
dc.identifier.citedreferenceCoffin CS, Shaheen AA, Burak KW, Myers RP. Pregnancy outcomes among liver transplant recipients in the United States: a nationwide case‐control analysis. Liver Transpl 2010; 16: 56 ‐ 63.en_US
dc.identifier.citedreferenceSifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698 ‐ 1702.en_US
dc.identifier.citedreferenceAnderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009; 149A: 1241 ‐ 1248.en_US
dc.identifier.citedreferenceHeneghan MA, Selzner M, Yoshida EM, Mullhaupt B. Pregnancy and sexual function in liver transplantation. J Hepatol 2008; 49: 507 ‐ 519.en_US
dc.identifier.citedreferenceEBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long‐term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 ( suppl 4 ): 50 ‐ 55.en_US
dc.identifier.citedreferenceChristopher V, Al‐Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, et al. Pregnancy outcome after liver transplantation: a single‐center experience of 71 pregnancies in 45 recipients. Liver Transpl 2006; 12: 1138 ‐ 1143.en_US
dc.identifier.citedreferenceSan Juan R, Aguado JM, Lumbreras C, Díaz‐Pedroche C, López‐Medrano F, Lizasoain M, et al.; for RESITRA Network (Spain). Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7: 964 ‐ 971.en_US
dc.identifier.citedreferenceHumar A, Snydman D; for AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 ( suppl 4 ): S78 ‐ S86.en_US
dc.identifier.citedreferenceRazonable RR. Cytomegalovirus infection after liver transplantation. Liver Transpl 2010; 16 ( suppl 2 ): S45 ‐ S53.en_US
dc.identifier.citedreferenceKotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al.; for Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779 ‐ 795.en_US
dc.identifier.citedreferenceAsberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al.; for VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106 ‐ 2113.en_US
dc.identifier.citedreferenceBurra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, et al. Occurrence of post‐transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006; 18: 1065 ‐ 1070.en_US
dc.identifier.citedreferenceJain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20‐year experience. Ann Surg 2002; 236: 429 ‐ 436.en_US
dc.identifier.citedreferenceAllen U, Preiksaitis J; for AST Infectious Diseases Community of Practice. Epstein‐Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 ( suppl 4 ): S87 ‐ S96.en_US
dc.identifier.citedreferenceKremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post‐transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6 ( pt 1 ): 1017 ‐ 1024.en_US
dc.identifier.citedreferenceBerenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus‐related graft cirrhosis after liver transplantation. Hepatology 2000; 32 ( pt 1 ): 852 ‐ 858.en_US
dc.identifier.citedreferenceKoch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder—the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein‐Barr virus. Liver Transpl 2007; 13: 904 ‐ 912.en_US
dc.identifier.citedreferenceSingh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73: 63 ‐ 67.en_US
dc.identifier.citedreferenceBerenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis‐centrifugation blood cultures in the detection of tissue‐proven invasive candidiasis. Disseminated versus single‐organ infection. Diagn Microbiol Infect Dis 1993; 17: 103 ‐ 109.en_US
dc.identifier.citedreferenceAlexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)β‐ D ‐glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48: 4083 ‐ 4088.en_US
dc.identifier.citedreferenceHope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609 ‐ 622.en_US
dc.identifier.citedreferenceFortún J, Martín‐Dávila P, Alvarez ME, Norman F, Sánchez‐Sousa A, Gajate L, et al. False‐positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 2009; 87: 256 ‐ 260.en_US
dc.identifier.citedreferenceWu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4: 183 ‐ 188.en_US
dc.identifier.citedreferenceDurkin M, Witt J, Lemonte A, Wheat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004; 42: 4873 ‐ 4875.en_US
dc.identifier.citedreferenceConnolly PA, Durkin MM, Lemonte AM, Hackett EJ, Wheat LJ. Detection of Histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 2007; 14: 1587 ‐ 1591.en_US
dc.identifier.citedreferenceMartin SI, Fishman JA; for AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 ( suppl 4 ): S227 ‐ S233.en_US
dc.identifier.citedreferenceAguado JM, Torre‐Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P. Tuberculosis in solid‐organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276 ‐ 1284.en_US
dc.identifier.citedreferenceSubramanian A, Dorman S; for AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 ( suppl 4 ): S57 ‐ S62.en_US
dc.identifier.citedreferenceYehia BR, Blumberg EA. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010; 16: 1129 ‐ 1135.en_US
dc.identifier.citedreferenceBlumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al.; for American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603 ‐ 662.en_US
dc.identifier.citedreferenceBlumberg EA, Stock P; for AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV‐infected patient. Am J Transplant 2009; 9 ( suppl 4 ): S131 ‐ S135.en_US
dc.identifier.citedreferenceCastells L, Escartín A, Bilbao I, Len O, Allende H, Vargas V, et al. Liver transplantation in HIV‐HCV coinfected patients: a case‐control study. Transplantation 2007; 83: 354 ‐ 358.en_US
dc.identifier.citedreferenceDanzinger‐Isakov L, Kumar D; for AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 ( suppl 4 ): S258 ‐ S262.en_US
dc.identifier.citedreferenceKim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680 ‐ 1686.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
23566_ftp.pdf
Size:
227.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.